Alvotech announced $323.4 million in adjusted revenue for the first nine months of 2026, down 23% year-over-year, but with a 78% increase in Q3 product revenue. The company achieved key FDA approvals for its biosimilar drugs Simlandi and AVT80, enhancing manufacturing capacity and pipeline progress. Despite a net loss due to financial costs, Alvotech maintains its 2026 revenue guidance of $650-$700 million and aims to ramp up product deliveries in Q4 while expanding its global manufacturing and commercial partnerships.
Alvotech's financial results for the first nine months of 2026 provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: Out of 150 priced US health-sector stocks, 87 rose and 61 fell today. Notable movers include BFLY at USD 7.23 with an 11.06% increase and a typical hold time of 16 days, BNGO at USD 1.10 down 10.57% with a 44% sell and 56% buy order activity and a 52-day hold, and ERAS at USD 16.83 up 8.72% with a 4-day hold time.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
